prostate cancer

3 new FDA drug approvalsFDA recently approved 3 major drugs to treat lung cancer, prostate cancer, and cystic fibrosis. Here are the top 3 new drug approvals.
PCa-specific mortality not affected by comorbidityComorbidity does not affect prostate cancer-specific mortality, according to authors of a large prospective observational study of men in Sweden, published in the Journal of Clinical Oncology (2017; 35:3566-74).
BMI predicts post-RP metastasis, prostate cancer mortalityBody mass index is an independent predictor of metastasis and prostate cancer mortality after radical prostatectomy, according to results from a large, long-term single-institution study.
Is favorable-risk GG2 prostate Ca suitable for active surveillance?"The management of prostate cancer always requires caution to safeguard against avoidable risks from both the treatment and the monitoring protocol," writes Badar M. Mian, MD.
Top 5 pipeline drugs for 2018
Top 5 pipeline drugs for 2018New blockbuster drugs to treat various conditions are expected to be among the top drugs to hit the marketplace in 2018. Here are 5 of the top new drugs in the pipeline for 2018, according to analysts.
Top 9 peer-reviewed prostate cancer papers of 2017Multiparametric MRI, USPSTF’s updated PSA screening recommendation, and the landmark STAMPEDE and LATITUDE trials were among this year’s highlights in the peer-reviewed literature for prostate cancer, according to Leonard G. Gomella, MD; Stacy Loeb, MD, MS; and J. Brantley Thrasher, MD.
Study: Active surveillance uptake remains lowThe overall use of active surveillance in men with low-risk prostate cancer is 14.2%, according to an examination of the National Cancer Data Base.
Tissue-based PCa assays not robust to multifocalityTissue-based prognostic biomarker assays for prostate cancer are not robust to tumor multifocality and heterogeneity, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.
Genomic testing linked to higher surveillance uptakeIn men with clinically low-risk prostate cancer managed in community-based urology practices, utilization of active surveillance as initial management is higher among those who undergo genomic testing.
CCP score further risk stratifies surveillance candidatesUse of a cell cycle progression genomics test (Prolaris) can further stratify risk in men who are candidates for active surveillance based on clinical criteria, and therefore may have a role in decision-making in men with early-stage prostate cancer, researchers say.